Zhejiang Orient Gene Biotech Co., Ltd.
SSE:688298.SS
26.59 (CNY) • At close June 10, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 827.916 | 820.157 | 8,767.938 | 10,169.168 | 3,265.356 | 367.377 | 285.893 | 224.237 | 182.255 |
| Cost of Revenue
| 565.13 | 467.403 | 4,314.399 | 2,665.325 | 677.778 | 192.854 | 146.748 | 116.33 | 94.621 |
| Gross Profit
| 262.786 | 352.755 | 4,453.539 | 7,503.843 | 2,587.578 | 174.523 | 139.145 | 107.907 | 87.634 |
| Gross Profit Ratio
| 0.317 | 0.43 | 0.508 | 0.738 | 0.792 | 0.475 | 0.487 | 0.481 | 0.481 |
| Reseach & Development Expenses
| 0 | 260.861 | 511.564 | 428.52 | 93.75 | 31.756 | 18.642 | 12.304 | 9.256 |
| General & Administrative Expenses
| 0 | 127.466 | 115.803 | 55.391 | 18.52 | 11.574 | 8.938 | 20.525 | 11.588 |
| Selling & Marketing Expenses
| 0 | 162.191 | 485.113 | 1,038.862 | 317.397 | 28.795 | 25.531 | 22.143 | 19.714 |
| SG&A
| 203.058 | 289.657 | 600.916 | 1,094.253 | 335.917 | 40.369 | 34.469 | 42.668 | 31.302 |
| Other Expenses
| 348.066 | 186.071 | 219.876 | 98.774 | 33.603 | 7.934 | 1.842 | 2.598 | 3.476 |
| Operating Expenses
| 841.617 | 736.589 | 1,332.356 | 1,621.547 | 463.27 | 80.059 | 65.072 | 56.238 | 42.531 |
| Operating Income
| -565.838 | -658.176 | 3,680.012 | 5,776.399 | 1,974.346 | 91.034 | 75.158 | 37.22 | 40.319 |
| Operating Income Ratio
| -0.683 | -0.803 | 0.42 | 0.568 | 0.605 | 0.248 | 0.263 | 0.166 | 0.221 |
| Total Other Income Expenses Net
| -19.473 | 253.95 | -57.458 | -6.433 | -0.065 | 0.263 | 1.842 | 2.599 | 3.476 |
| Income Before Tax
| -585.311 | -404.227 | 2,470.752 | 5,769.966 | 1,974.281 | 91.297 | 77 | 39.818 | 43.796 |
| Income Before Tax Ratio
| -0.707 | -0.493 | 0.282 | 0.567 | 0.605 | 0.249 | 0.269 | 0.178 | 0.24 |
| Income Tax Expense
| -16.488 | 14.042 | 373.321 | 829.32 | 293.95 | 13.789 | 13.044 | 7.112 | 8.169 |
| Net Income
| -529.023 | -397.584 | 2,067.714 | 4,920.188 | 1,677.359 | 82.105 | 65.37 | 33.357 | 35.627 |
| Net Income Ratio
| -0.639 | -0.485 | 0.236 | 0.484 | 0.514 | 0.223 | 0.229 | 0.149 | 0.195 |
| EPS
| -2.6 | -1.97 | 12.31 | 34.17 | 8.5 | 0.54 | 0.43 | 0.22 | 0.4 |
| EPS Diluted
| -2.6 | -1.97 | 12.31 | 34.17 | 8.5 | 0.54 | 0.43 | 0.22 | 0.4 |
| EBITDA
| -359.684 | -199.979 | 2,564.279 | 5,811.927 | 1,981.765 | 101.523 | 88.206 | 48.316 | 56.266 |
| EBITDA Ratio
| -0.434 | -0.244 | 0.292 | 0.572 | 0.607 | 0.276 | 0.309 | 0.215 | 0.309 |